Virax Biolabs Group Limited (VRAX) Stock Price, Quote & News

Company Profile

Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7788 7414

Website: viraxbiolabs.com

Address:

BioCity Glasgow, Bo’Ness Road Newhouse, Lanarkshire, United Kingdom

Chief1912 Mar. 13 at 1:18 AM

$VRAX this seemed pinned. Jeez.

0 · Reply

uppons Mar. 12 at 3:40 AM

$VRAX 1tp!!

2 · Reply

Yung_Ball3R Mar. 9 at 1:36 PM

$VRAX Held steady this past week

0 · Reply

StealthKing Mar. 7 at 8:28 AM

$VRAX The primary driver for VRAX right now is the transition from clinical planning to data generation for its ViraxImmune™ diagnostic platform

1 · Reply

TraderBuckNKY Mar. 4 at 8:08 PM

$VRAX ...quick summary for all believers...: Annual General Meeting (AGM): The company has scheduled its AGM for March 11, 2026, where shareholders will vote on a proposed reverse share split and a new equity plan. Clinical Progress: In late 2025, Virax completed recruitment for its UK clinical study on ViraxImmune™, a platform for T-cell dysfunction in post-viral syndromes like Long COVID. Initial data from this study is expected in Q2 2026. Strategic Partnerships: The company recently partnered with Emory University to support its U.S. regulatory goals and signed an exclusive distribution agreement for Mpox PCR detection kits with Cosmos Health Inc.. Capital Raising: A $5 million private placement closed in December 2025, intended to extend the company's cash runway into the first half of 2028.

0 · Reply

ucla44life Mar. 3 at 3:37 PM

$VRAX Teens :-)....trips coming weeeeeeeeeeeeeeeee

0 · Reply

OfficialStocktwitsUser Mar. 3 at 2:05 PM

$VRAX RSI: 46.67, MACD: -0.0213 Vol: 0.02, MA20: 0.23, MA50: 0.29 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

1 · Reply

6GodEnergy Feb. 25 at 7:16 PM

$SBET $VRAX $UIS $GGR *^*^

0 · Reply

ucla44life Feb. 25 at 3:41 PM

$VRAX SCAM RUN BY A CON

0 · Reply

Yung_Ball3R Feb. 24 at 7:49 PM

$VRAX

4 · Reply

Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

Dec 3, 2025, 1:53 PM EST - 3 months ago

Virax Biolabs Group Limited Announces $5 Million Private Placement

Dec 3, 2025, 7:34 AM EST - 3 months ago

Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders

Nov 3, 2025, 8:29 AM EST - 4 months ago

Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes

Aug 26, 2025, 7:30 AM EDT - 7 months ago

Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

Jul 29, 2025, 7:35 AM EDT - 8 months ago

Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

Jul 18, 2025, 4:15 PM EDT - 8 months ago

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

Mar 31, 2025, 2:57 PM EDT - 1 year ago

Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating

Mar 18, 2025, 7:30 AM EDT - 1 year ago

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

Mar 13, 2025, 7:30 AM EDT - 1 year ago

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

Mar 5, 2025, 7:30 AM EST - 1 year ago

Virax Biolabs to Present at 19th World Immune Regulation Meeting

Feb 25, 2025, 7:00 AM EST - 1 year ago

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

Jan 23, 2025, 3:35 PM EST - 1 year ago

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

COSM

Jan 13, 2025, 9:20 AM EST - 1 year ago

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

COSM

Dec 17, 2024, 7:30 AM EST - 1 year ago

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

Dec 10, 2024, 7:30 AM EST - 1 year ago

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar

COSM

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.

COSM

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference

Aug 29, 2024, 9:03 AM EDT - 1 year ago

Virax Biolabs to Participate at 7th European Congress of Immunology

Aug 28, 2024, 2:18 PM EDT - 1 year ago

Virax Biolabs stock soars 45% on Mpox detection kit deal: What you need to know

Aug 28, 2024, 7:30 AM EDT - 1 year ago

Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East

Aug 23, 2024, 4:09 PM EDT - 1 year ago

Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Aug 21, 2024, 9:30 PM EDT - 1 year ago

Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares

Aug 21, 2024, 10:20 AM EDT - 1 year ago

Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits

COSM

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024

Apr 16, 2024, 7:30 AM EDT - 2 years ago

Virax Biolabs to Participate at ESCMID Global 2024

Dec 21, 2023, 7:30 AM EST - 2 years ago

Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients

Dec 14, 2023, 7:30 AM EST - 2 years ago

Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation

Sep 12, 2023, 7:30 AM EDT - 2 years ago

Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar

Sep 1, 2023, 7:30 AM EDT - 2 years ago

Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid

Jul 18, 2023, 7:30 AM EDT - 2 years ago

Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities

May 4, 2023, 7:30 AM EDT - 3 years ago

Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park

Apr 19, 2023, 7:30 AM EDT - 3 years ago

Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits

Mar 10, 2023, 5:17 PM EST - 3 years ago

Virax Biolabs Group Limited Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 8, 2023, 8:55 AM EST - 3 years ago

Virax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 7, 2023, 7:30 AM EST - 3 years ago

Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit

Feb 7, 2023, 9:15 AM EST - 3 years ago

Cosmos Health Announces Initial Purchase Order with Virax Biolabs for the Distribution of COVID-19 and Influenza A+B Antigen Combo Rapid Tests

COSM

Feb 7, 2023, 8:30 AM EST - 3 years ago

Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health (NASDAQ:COSM)

COSM

Feb 6, 2023, 4:05 PM EST - 3 years ago

Virax Biolabs to Present at the 2023 BIO CEO & Investor Conference

Jan 4, 2023, 7:30 AM EST - 3 years ago

Virax Biolabs Introduces Human Papillomavirus ("HPV") Test Kit

Dec 6, 2022, 7:30 AM EST - 3 years ago

COVID-19 Rapid Antigen Test Distributed By Virax Biolabs Receives Emergency Use Authorization in the United States

Nov 15, 2022, 7:30 AM EST - 3 years ago

Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales

Nov 8, 2022, 4:30 PM EST - 3 years ago

Virax Biolabs Group Limited Announces Closing of $3.8 Million Private Placement

Nov 4, 2022, 7:30 AM EDT - 3 years ago

Virax Biolabs Group Limited Announces $3.8 Million Private Placement

Nov 3, 2022, 7:30 AM EDT - 3 years ago

Virax Biolabs Introduces RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit

Oct 26, 2022, 7:30 AM EDT - 3 years ago

Virax Biolabs Group Limited Announces Initiation of its Virax Immune COVID-19 Analytical Performance Study

Sep 22, 2022, 8:07 AM EDT - 3 years ago

Virax Biolabs Group Limited Announces Distribution Agreement to Market Monkeypox Virus Real-Time PCR Detection Kit with Cosmos Holdings Inc.

COSM

Chief1912 Mar. 13 at 1:18 AM

$VRAX this seemed pinned. Jeez.

0 · Reply

uppons Mar. 12 at 3:40 AM

$VRAX 1tp!!

2 · Reply

Yung_Ball3R Mar. 9 at 1:36 PM

$VRAX Held steady this past week

0 · Reply

StealthKing Mar. 7 at 8:28 AM

$VRAX The primary driver for VRAX right now is the transition from clinical planning to data generation for its ViraxImmune™ diagnostic platform

1 · Reply

TraderBuckNKY Mar. 4 at 8:08 PM

0 · Reply

ucla44life Mar. 3 at 3:37 PM

$VRAX Teens :-)....trips coming weeeeeeeeeeeeeeeee

0 · Reply

OfficialStocktwitsUser Mar. 3 at 2:05 PM

1 · Reply

6GodEnergy Feb. 25 at 7:16 PM

$SBET $VRAX $UIS $GGR *^*^

0 · Reply

ucla44life Feb. 25 at 3:41 PM

$VRAX SCAM RUN BY A CON

0 · Reply

Yung_Ball3R Feb. 24 at 7:49 PM

$VRAX

4 · Reply

ucla44life Feb. 23 at 6:50 PM

$VRAX It just keeps getting worse and worse for this SCAM....If only there was someone telling us this was a SCAM since well over $4, we probably wouldn't be in this bag holder situation with absolutely no hope in sight except a R/S or trips...If only there was somebody :-) Delisting should be occurring at some point for failure to meet listing requirements. Have fun with trips or dilution...STINKY PINKY PEEEEEEEEE YEWWWWWWWWWWWW WHAT A SCAM!!!

0 · Reply

TraderBuckNKY Feb. 23 at 3:42 PM

$VRAX ...dear God, please tell me UCLA wasn't right all this time...I really (and I guess very naively) expected the Emory University news to turn into something...it's like a really bad BeeGees Song... https://youtu.be/6l1S5N41XdM?si=eBJsBRUI0Rl60eGG

0 · Reply

BlackForge Feb. 22 at 1:28 AM

$VRAX The company’s operations and R&D efforts are largely funded through equity issuances and capital markets rather than strong internal cash generation. This dependence increases the risk of share dilution, which can erode existing shareholder value if frequent financings are needed..

1 · Reply

BlackForge Feb. 22 at 1:27 AM

$VRAX Reliance on External Financing & Dilution Risk.

0 · Reply